Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05417932 · ClinicalTrials.gov registry record · Phase 1
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
A Phase 1 study of Hepatocellular Carcinoma Recurrent and Hepatitis B Virus Related Hepatocellular Carcinoma, sponsored by SCG Cell Therapy Pte..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 6
- Study locations
NCT05417932: Recruiting Phase 1 study of Hepatocellular Carcinoma Recurrent and Hepatitis B Virus Related Hepatocellular Carcinoma, sponsored by SCG Cell Therapy Pte..
NCT05417932 is a Phase 1 study of Hepatocellular Carcinoma Recurrent and Hepatitis B Virus Related Hepatocellular Carcinoma that is actively recruiting participants, run by SCG Cell Therapy Pte.. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05417932, a Phase 1 study of Hepatocellular Carcinoma Recurrent and Hepatitis B Virus Related Hepatocellular Carcinoma, is actively recruiting participants, sponsored by SCG Cell Therapy Pte..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 6
- Study locations
Study Summary
This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
Primary Outcome
Based on incidence of adverse events (AE) using NCI-CTCAE v5.0
Conditions Studied
Interventions
- BIOLOGICAL SCG101
Study Locations (6)
Other
- Hong Kong is. - Hong Kong
- Hong Kong NT - Hong Kong
- Singapore - Singapore
- Singapore - Singapore
New York
- New York - New York
- New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2025-10 |
| Phase | Phase 1 |
What NCT05417932 shows while recruiting
NCT05417932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 2 conditions, with Hepatocellular Carcinoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which SCG101 is the first listed.
NCT05417932 lists 6 locations in 2 states (Other, New York).
Frequently Asked Questions
What is clinical trial NCT05417932 about?
NCT05417932 is a clinical study titled "A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma". This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
What is the current status of trial NCT05417932?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2022-10-26. Estimated completion is 2025-10.
What conditions does trial NCT05417932 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma Recurrent, Hepatitis B Virus Related Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05417932?
The interventions under investigation include: SCG101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05417932?
This trial is sponsored by SCG Cell Therapy Pte., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05417932 being conducted?
This trial has 6 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05417932's enrollment target sits among peer trials
46 1059th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI